Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2015 March;59(1) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2015 March;59(1):83-94

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413


eTOC

 

REVIEWS  SECOND GENERATION PET TRACERS IN ONCOLOGY


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2015 March;59(1):83-94

lingua: Inglese

Applications of PET imaging with radiolabelled choline (11C/18F-choline)

Kirienko M. 1, Sollini M. 2, Lopci E. 3, Versari A. 2, Chiti A. 3

1 Department of Nuclear Medicine, Milano‑Bicocca University, Milan, Italy,
2 Nuclear Medicine Unit, Department of Oncology and Advanced Technology, Arcispedale Santa Maria Nuova, IRCCS, Reggio Emilia, Italy;
3 Department of Nuclear Medicine, Humanitas Research Hospital, Rozzano (MI), Italy


PDF  


The use of radiopharmaceuticals is the distinguishing characteristics of nuclear medicine. Among the panel of available radiopharmaceuticals in many PET centers around the world, choline is well represented, being widely used to image prostate cancer. Carbon-11 labelled choline can only be produced in centres with a cyclotron available, but the 18F-labelled radiopharmaceutical is distributed and licensed in several countries in Europe. Besides prostate cancer, other possible uses of choline are related to its ability to indirectly evaluate the cell proliferation as a measure of the synthesis of lipids required for cell membrane. In particular, the radiopharmaceutical can be successfully used in those districts where 18F-FDG has a high uptake, like the brain. Moreover, slow growing tumors, not always taking up 18F-FDG, like hepatocellular carcinoma, can also be imaged. We will evaluate possibly uses of this molecule in patients affected by prostate cancer, brain tumors and hepatocellular carcinoma.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail

arturo.chiti@humanitas.it